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Research has suggested that negative symptoms in psychotic disorders may be in part be 
fueled by deficits in metacognition or the ability to form integrated idea about oneself in 
others. One limitation of this work is that it has largely come from North America and 
Western Europe. To further the literature, we assessed symptoms using the Positive and 
Negative Syndrome Scale and Metacognition using the Metacognitive Assessment Scale - 
Abbreviated in a sample of outpatients with prolonged schizophrenia (n=41), early episode 
psychosis (n= 37) and major depression (n=30) gathered in Moscow, Russia. Verbal memory 
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was assessed for use as a potential covariate. ANOVA revealed the two groups with 
psychosis has significantly poorer metacognitive function in terms of self-reflectivity and 
awareness of the other, than the group with depression. In both psychosis groups negative 
symptoms were more robustly related to metacognition than other forms of symptoms after 
controlling for neurocognition. Results support the possibility that metacognitive deficits are 
a psychological factor which cross culturally contributes to negative symptoms and point to 
metacognition as a potentially important target for intervention. 
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Metacognition; psychosis; schizophrenia; neurocognition, depression; recovery; social 
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1. Introduction
Research carried out by both clinical scientists as well as persons with first person 
experience, have confirmed long standing assertions that the way persons with schizophrenia 
spectrum disorders make sense of mental health challenges has a deep influence over how 
well they can manage those challenges (Leonhardt et al., 2017; Lysaker and Lysaker, 2017). 
One factor which has a lasting effect on persons abilities to make sense of mental health 
challenges is metacognition (Lysaker et al., 2019a). Metacognition has been examined in 
studies within the fields of educational, developmental, cognitive, and abnormal psychology 
(e.g. Semerari et al., 2003; Taricone, 2011), and refers to a broad set of processes which 
allow persons to be aware of what is happening in their minds, reflect upon those activities 
and use that to monitor and change their own behavior (Moritz and Lysaker, 2018).  In what 
has been referred to as the integrative model of metacognition, metacognition has been 
conceptualized as a capacity which allows for the integration of cognition, emotion and 
embodied experiences into a larger sense of oneself and others. This larger sense of oneself 
and others then allows for interpretations of novel experience within the flow of life and 
determination of what is uniquely adaptive for oneself (Lysaker et al., 2019b).  
Applied to schizophrenia, decrements in metacognitive capacity have been suggested 
to limit how well persons can form an integrated sense of the problems posed by 
schizophrenia, leaving them less able to find effective ways to overcome them. Evidence 
supporting this includes findings that persons with schizophrenia experience relatively 
greater deficits in metacognition and that greater metacognitive deficit predicts poorer 
outcome (c.f. Lysaker et al., 2019a). Notably, metacognition has not just been linked to 
concurrent function but in several studies to prospective levels of negative symptoms 
(Austin et al., 2019; Hamm et al., 2012; McLeod et al., 2015; Lysaker et al., 2015). This has 
led to the tantalizing possibility that the paucity of internal experience and expression of 
affect which characterize negative symptoms are in part a function of the loss of kinds of 
larger sense of self which serve as the context which imbues specific experiences with 
unique meaning (Lysaker et al., 2019a). 
As these advances have spurred the development of metacognitive treatment 
approaches (de Jong et al., 2019; Lavi-Rotenberg et al, in press; Lysaker and Klion, 2017; 
Vohs et al., 2018), one limitation is that since most of the work has come from North 
America, the Middle East or Western Europe the possibility has been left open that observed 
findings were influenced by cultural factors (e.g., Austin et al., 2019; Bröcker et al., 2017; 
Inchausti et al., 2017; Lysaker et al., 2019a; Popolo et al., 2017). Further, few comparisons 
have been made between the relationship of metacognitive capacity with negative symptoms 
across different phases of schizophrenia as well as in other forms of serious mental illness, 
in particular depression. Research is thus needed with more diverse samples that include 
individuals from other cultures, where linguistic differences and cultural history may 
influence how persons integrate and use information about themselves and others.  
To study this issue, we assessed metacognitive capacity and symptoms in three 
groups gathered in Russia. The three groups were comprised of patients with confirmed 
diagnoses of prolonged schizophrenia, early episode psychosis and major depression. We 
predicted that both psychosis groups would demonstrate poorer overall metacognition than 
the depression group. While no study has previously directly compared these groups, the 
mean metacognitive scores reported by Ladegaard (2014) for participants with major 
depression are numerically higher than those reported in most schizophrenia samples (e.g., 
Hasson-Ohayon, 2015). We further predicted that metacognition would be significantly 
related to negative symptoms in both psychosis groups but not necessarily in the depression 
group. We anticipated this given the theoretical possibility that negative symptoms in 
psychosis may arise or be sustained by metacognitive deficits as well as previous empirical 
research suggesting that anhedonia is uniquely related to poor metacognition in 
schizophrenia in the absence of depressed mood (Buck et al., 2014).  
While our predictions concerned overall metacognitive capacity, we planned to 
analyze specific elements of metacognition for exploratory purposes. These included scores 
that measure metacognitive capacities for self-reflection, reflection about others, 
decentration (i.e., reflection about one’s place in one’s community) and mastery (i.e., the use 
of this knowledge to respond to psychosocial challenges). Given research has distinguished 
between experiential and expressive negative symptoms, and suggested metacognition is 
more closely related to the later (Austin et al., 2019) we also planned exploratory analyses to 
determine whether metacognitive capacity was more closely related to one of these forms of 
negative symptoms. To rule out the possibility that any findings might be the result of 
general associations with psychopathology we included assessments of other forms of 
symptoms including positive symptoms. Lastly, to rule out the possibility that results may 
reflect general neurocognitive compromise we included assessment of verbal memory, one 
of the most affected of neurocognitive abilities in schizophrenia (Saykin et al., 1991).  
2.1. Participants 
Participants were adults diagnosed with prolonged schizophrenia (n = 41), early 
psychosis (n = 37), and major depression (n = 30). All were recruited from the out-patient 
departments of Alexeev mental-health clinic No.1 in Moscow. Diagnoses were determined 
according to ICD-10 by the treating medical staff following a routine diagnostic clinical 
interview that included personal, clinical and medical history and chart review. The 
interview contained detailed questions about the onset, course and notable episodes of 
symptoms of psychosis and depression as well as other features which might rule out these 
diagnoses including mood elevation, medical, behavioral and substance use symptoms. Early 
psychosis was defined as psychotic symptoms beginning for the first time no more than 5 
years earlier with no more than three distinct psychotic episodes occurring since then. 
Prolonged schizophrenia was defined as meeting criteria for schizophrenia for a minimum 
of 6 years as determined during the clinical interview. Exclusion criteria included a 
cognitive impairment severe enough such that informed consent could not be attained, 
current alcohol 
or drug addiction, neurological disorders, or hospitalizations in the last month, all determined 
by the clinical interview and thorough chart review. 
2.2. Instruments 
2.2.1. Indiana psychiatric illness interview (IPII; Lysaker et al., 2002) The IPII is a semi-
structured interview that asks participants to describe their understanding of their mental 
illness and psychological challenges. First, participants are asked to offer a narrative about 
their lives and then asked whether they believed they have a mental illness. Next participants 
are asked about what has changed since having a mental illness, and how they controlled 
their mental illness versus what ways it controlled their lives. Participants are then asked 
how their condition both affects and is affected by others. Finally, participants are asked 
what they expect will be the same or different for them in the future. Interviews are 
audiotaped at the time of the interview and are later transcribed. Interviews generally take 20 
to 50 minutes and are conducted by 
trained interviewers. 
2.2.2. Metacognition assessment scale-abbreviated (MAS-A; Lysaker et al., 2019a). The 
MAS-A is a rating scale used to evaluate that which enables an integrated sense of oneself 
and others to be available to persons. The MAS-A was developed following the original 
Metacognitive Assessment Scale (Semerari et al., 2003). The MAS-A retains the original 
four subscales created by Semerari et al. (2003): Self-reflectivity (S), Understanding other's 
minds (O), Decentration (D), and Mastery (M). In contrast to the MAS, however, the MAS-
A is an ordinal scale and items are arranged such that each item of each scale describes a 
more complex metacognitive activity than the item numerically before it. In the MAS-A 
each item, therefore, requires the integration of a kind of information that was not integrated 
in the previous lower item (e.g., level “5” would require the integration of a form of 
information not found in level “4”). Accordingly, metacognition is conceptualized and 
operationalized as a series of hierarchical steps and the score for a given scale then is the 
number of contiguous items successfully  achieved on that scale. Evidence of reliability and 
validity have been reported elsewhere (Lysaker and Dimaggio, 2014). A Russian version of 
the IPII along with the MAS-A codebook for scoring metacognition were translated by the 
authors and used in the current study. 
2.2.3. Positive and negative syndrome scale (PANSS; Kay et al., 1987). The PANSS assesses 
multiple dimensions of symptoms of schizophrenia as well as other forms of serious mental 
illness. It contains 30 items. In this research we used a five-factor solution (Bell et al., 1994) 
which produces five component symptom scores: Positive, Negative, Cognitive, Excitement/ 
Hostility, and Emotional Discomfort. To explore the two forms of negative symptoms, 
experiential and expressive we used the formula proposed by Khan et al., (2017) in which 
expressive symptoms are estimated as the sum of blunted affect, poor rapport, lack of 
spontaneity, and motor retardation and experiential symptoms as the sum of emotional 
withdrawal, passive/apathetic social withdrawal, and active social avoidance. 
2.2.4 Luria 10 word Test (Rubinstein, 2010). The Luria 10 word test consists of 5 trials in 
which 10 unrelated words are read to the participant who then is asked repeat as many as 
they can remember. The score used here is the total number of correct responses across all 
trials. 
2.3. Procedures 
All procedures were approved by the local ethics committee at the Alexeev mental-health 
clinic No.1. Following informed consent and evaluation of inclusion and exclusion criteria, 
diagnoses were confirmed by senior clinicians, according to clinical interviews. The IPII, 
PANSS and Luria 10 word test were completed by a trained interviewer with a degree in 
medical psychology. IPII interviews were transcribed and rated by trained raters trained by 
the author of the MAS-A (PL). MAS-A and PANSS raters were blind to other scores. 
2.4. Data analysis 
Analyses were conducted in five steps using SPSS version 24. First, we planned to 
compare the demographic characteristics, PANSS, and Luria 10 word memory scores of the 
three groups in order to characterize them. Second, we planned to compare the MAS-A 
scores between groups using an MANOVA with Fischer Least Squared Difference tests to 
compare individual groups on individual measures. Third we planned to correlate the MAS-
A with the PANSS and Luria 10 item memory scores for the three groups separately.  Given 
the likelihood that MAS-A scores would not be normally distributed we planned to use 
Spearman correlation coefficients. Fourth, in case the MAS-A total was related to the 
PANSS Negative component we planned to explore the relationship of MAS-A scores with 
the two different dimensions of negative symptoms: experiential and expressive symptoms. 
Given the large number of correlations we planned to first consider whether there was a 
significant correlation between symptoms and the MAS-A total and then only consider the 
MAS-A subscales for exploratory purposes when that overall relationship exists. Finally, in 
a case of positive relationships found in the four step we plan partial correlations between 
the MAS-A scores and negative symptoms in general as well as the expressive and 
experiential negative symptoms controlling for potential covariates.   
3. Results
To characterize each group, age, gender, education and key test scores are presented 
in Table 1. This table reveals that multivariate and univariate tests found that the early 
psychosis and depression groups were significantly younger than the prolonged psychosis 
group. Education level was not significantly different across groups. Proportions of men and 
women were equivalent across groups. Both psychosis groups performed more poorly on the 
Luria memory test than the depression group. Considering overall psychopathology, the 
prolonged schizophrenia group had higher symptom scores on the PANSS than the early 
psychosis group which had higher symptom scores than the depression group.  
Next as revealed in Table 1, ANOVA followed by Fischer Least Difference tests 
indicated that the prolonged psychosis group had significantly lower MAS-A total scores 
than the depression group with the early psychosis group having a MAS-A total score that 
was not significantly different than either group. When subscales were examined, however 
the prolonged psychosis group had significantly lower self-reflectivity and awareness of 
other than both the early psychosis and depression groups. The early psychosis group further 
had significantly lower decentration scores than the prolonged schizophrenia and depression 
groups. The prolonged schizophrenia group had uniquely poor levels of mastery compared to 
the other two groups. 
To explore the link of metacognition with PANSS component scores and Luria 10 
word memory test, Spearman correlations were next calculated separately per group. As 
revealed in Table 2, multiple MAS-A scores were significantly correlated with the negative 
symptom component in both the prolonged schizophrenia and early psychosis groups. No 
other relationships were found between the MAS-A total and PANSS components. When we 
examined the MAS-A subscales it appears that the self-reflectivity subscale had the strongest 
numerical relationship with negative symptoms. The Luria 10 word and MAS-A total were 
significantly and negatively correlated in both the psychosis samples. 
Given the link of MAS-A total with the PANSS component we next explored 
whether the MAS-A total was more closely linked with experiential vs expressive negative 
symptoms on the PANSS. Spearman correlations revealed that the MAS-A total was 
significantly related to both experiential and expressive negative symptoms in the prolonged 
(r = 0.34, p< .05; r = 0.47, p< .01 respectively) and early episode psychosis groups (r = 
-0.38, p< .05; r = -0.40, p< .05 respectively).  
Finally, to rule out the possibility that any observed relationships were the results of 
demographic or other relevant symptom variables we conducted two stepwise regressions. 
For each, we created an equation to predict the PANSS negative symptom total first 
allowing age, and then the Luria memory score to enter, and then in a second step finally 
allowing MAS-A total to enter. For the prolonged schizophrenia this revealed a significant 
predictor equation (F(2,40) =  5.20; p < .01) in which 12% of the variance was explained in 
the first step by the Luria score, and 9% in the second step by the MAS-A total. For the early 
episode psychosis group, this revealed a significant predictor equation (F(2,34) =  6.40; p 
< .01) in which 18% of the variance was explained in the first step by the Luria score, and 
5% in the second step by the MAS-A total. Finally, we repeated the correlations between the 
MAS-A total the experiential and expression PANSS negative symptom scores as partial 
correlations, controlling for age and the Luria memory scores. For the prolonged sample, the 
relationship of experiential and expressive negative symptoms with MAS-A total both 
remained significant (r= -0.35 p = .03; (r = -0.40 p = .01). For the early psychosis group, the 
relationship of experiential and the MAS-A total remained significant (r= -0.35 p = .03) 
while the relationship of expressive symptoms and the MAS-A total became non-significant 
(r=-.29, p=.09). 
4. Discussion
In this study we sought to expand previously research by exploring the relationship 
between metacognition and negative symptoms among adults with mental illness in setting 
outside of North American and Western Europe in order explore whether similar 
relationships would be observed.  We also examined the same phenomenon in control group 
not previously directly compared with persons with psychosis, namely depression.  First, 
generally consistent with our predictions, we found that the patients with prolonged 
schizophrenia had significantly greater deficits in metacognitive function than the 
depression group. Both the prolonged schizophrenia and early psychosis group were less 
able to form complex integrated ideas about themselves and others relative to the depression 
group. The prolonged schizophrenia group had significantly greater difficulties than other 
groups using that metacognitive knowledge to characterize and respond to psychological 
problems. This study is thus the first to  replicate a range of previous studies (Lysaker et al., 
2019b) in a Russian sample and is the largest and only the third study (after WeiMing et al., 
2015a, 2015b; Lysaker et al., 2018) to be conducted outside North America, the Middle East 
or Western Europe. Given that both self-experience, the experience and expression of 
internal states and manifestations of psychopathology are all in part influenced by multiple 
factors including culture (Dimasio, 2010; Alarcon, 2009; Vermeiden et al., 2019), it is 
possible that previous associations between negative symptoms and metacognition were 
specific to the cultures in which they were studied. This study thus offers important new 
evidence suggesting at least a relationship between metacognition and social cognition 
which extends 
even further beyond specific cultural boundaries. This study was also the first to directly 
compare major depression with schizophrenia and so also provides further confirmation of 
uniquely severe levels of metacognitive impairments that may be present in schizophrenia 
across our world. 
Second, as predicted, we found greater impairments in overall metacognition in both 
psychosis groups were related to negative symptoms in general as well as lesser abilities in 
the metacognitive domains of self-reflectivity and awareness of the other. These 
relationships persisted when controlling for deficits in memory which were also linked with 
metacognition in both groups. Concerning subtypes of negative symptoms, we found 
overall metacognition was linked with experiential and expressive negative symptoms in 
both psychosis groups. When memory and age were controlled for statistically, 
metacognition remained significantly correlated with experiential symptoms in both groups 
and with expressive symptoms only in the prolonged schizophrenia group.  
While the cross-sectional nature of this study precludes drawing any causal 
conclusions, results may point to important hypotheses which could be tested in future 
research. For one, results may suggest that negative symptoms are not entirely a primary 
phenomenon, but consequences of compromises in the ability to integrate information and 
derive the kinds of meanings which make certain experiences more salient and so privilege 
certain motivations above others. For example with a profoundly fragmented experience of 
oneself in the world it would seem likely that any number of activities would have the same 
relative and limited meaning and there would be no reason to pursue one course of action 
over the other. If certain goals did not stand out with highly personal meaning. there might 
also be less of a reason to persist when facing challenges. There might also be less effective 
expression of emotion if with metacognitive deficits persons found it relatively difficult to 
know how to characterize and express their experiences in a way that others could 
understand them. This may be consistent with a range of older psychodynamic accounts of 
psychosis which the processes by which persons and others are unique beings are damaged 
and with the loss of genuine uniqueness, nothing if left to meaningfully distinguish the larger 
meaning of one activity from another. Examples of this include the work of Matte-Blanco’s 
as presented by Saks & Tsepilovan (2019) and Arieti’s (1955) characterization of 
schizophrenia as a disorder of symbolization. Of note, rival hypotheses cannot be ruled out 
including the possibility that negative symptoms cause metacognitive deficits or that both are 
the result of underlying psychophysiological processes not assessed here.  
There were unexpected findings. There were paradoxical aspects of the metacognitive 
function in the early psychosis group. They had lower decentration than any of the other two 
groups. This is consistent with Vohs et al., (2014) who reported particularly low levels of 
decentration in a early episode compared to a prolonged psychosis sample. It also raises the 
question, for further study, of  whether there are particular psychopathological processes 
(e.g. related to grandiosity) which may be linked to these unique decrements in decentration 
early on in psychosis. Yet mastery in the early episode group was higher than in the 
prolonged schizophrenia group. This may suggest that perhaps Mastery was yet to be as 
degraded as it was in the prolonged group, perhaps secondary to demoralization. The MAS-
A total of the early episode group was not significantly lower than in the depression group. 
This may suggest as just noted that not all metacognitive abilities become compromised 
simultaneously. With further study one potential implication of this is that early interventions 
in psychoses may explore their potential to prevent or slow the erosion of mastery in the 
course of schizophrenia.  As with all unexpected findings, replication is needed and 
hypotheses should be taken only as motivation for future research.  
There are limitations. Sample sizes were modest and participants were groups 
recruited to be enrolled in treatment. Results may therefore not be generalizable to groups of 
persons who decline treatment or participation in research. Variables were assessed at one 
time point and so conclusions regarding causality and the nature of the relationship of 
metacognition and symptoms cannot be drawn. Additionally, factors not assessed here may 
contribute to the phenomena observed, including history of trauma, disturbance in 
underlying brain function and degree of internalized stigma. Research is needed in the future 
that considers a broader sample and longitudinal designs. We also utilized only one measure 
of metacognition and neurocognition. Future research is needed which deploys a wider set of 
assessments. Finally, this is the first study to use the Russian translation of the MAS-A and 
more work is needed to explore its psychometric properties 
Finally, with replication in ever broader samples results may have clinical 
implications. If metacognitive capacities contribute to the development of negative 
symptoms and a route to recovery cross-culturally, integrative interventions that target 
metacognition might be worthy of further exploration. To date one of these, has been found 
to be  acceptable by Dutch (de Jong et al., 2018), French (Dubreucq et al., 2016) and Hebrew 
(Hasson-Ohayon et al., 2017) speaking patients as well as English speaking patients in 
Australia (Bargenquast and Schweitzer, 2013) with psychosis. It may also be that other 
treatments which similarly address metacognition may also potentially impact negative 
symptoms as well. 
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